When is it OK to violate your cost basis to buy more shares of a company?

When is it OK to violate your cost basis to buy more shares of a company?


Nvidia CEO Jensen Huang,speaks at the Supermicro keynote presentation during the Computex conference in Taipei on June 1, 2023.

Walid Berrazeg | Sopa Images | Lightrocket | Getty Images

Here’s our Club Mailbag email [email protected] — so you send your questions directly to Jim Cramer and his team of analysts. We can’t offer personal investing advice. We will only consider more general questions about the investment process or stocks in the portfolio or related industries.

This week’s question: The cardinal rule of discipline is to not violate cost basis and show patience to buy more high-quality stocks on pullback. How do you evaluate a flying stock which might not come back to levels of cost basis to add more? Recent examples include Nvidia (NVDA), Eli Lilly (LLY) and Tesla (TSLA). — Thanks, Ravi



Source

Supreme Court allows Trump’s cuts to health research grants over DEI policies
Health

Supreme Court allows Trump’s cuts to health research grants over DEI policies

The Supreme Court on Thursday allowed Trump administration broad cuts to National Institutes of Health grants as part of the federal government’s campaign against diversity, equity and inclusion policies. But in a mixed decision the court left in place a different part of the lower court judge’s ruling that threw out the administration’s guidance document that introduced the policy, […]

Read More
Microplastics are everywhere. Here’s why that matters to big oil
Health

Microplastics are everywhere. Here’s why that matters to big oil

Microplastics are increasingly being found in our bodies and food supply.  They are defined as pieces of plastic smaller than 5 millimeters — about the size of a pencil eraser. But they can also be much smaller, like the size of a virus particle or a strand of DNA. Petrochemicals, the building blocks of plastic, […]

Read More
FDA approves first-ever glucose monitoring system for weight loss from Signos 
Health

FDA approves first-ever glucose monitoring system for weight loss from Signos 

Woman with Signos wearable and app Source: Signos The Food and Drug Administration on Wednesday approved the first-ever glucose monitoring system specifically for weight loss from the startup Signos, establishing a new option for Americans to manage their weight.  Current treatment options for losing weight – popular drugs like GLP-1s and surgical interventions – are […]

Read More